Integrin modulators: a patent review

Integrins are heterodimeric cell surface receptors, which enable adhesion, proliferation, and migration of cells by recognizing binding motifs in extracellular matrix (ECM) proteins. As transmembrane linkers between the cytoskeleton and the ECM, they are able to recruit a huge variety of proteins an...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on therapeutic patents Vol. 23; no. 10; p. 1273
Main Authors Kapp, Tobias G, Rechenmacher, Florian, Sobahi, Tariq R, Kessler, Horst
Format Journal Article
LanguageEnglish
Published England 01.10.2013
Subjects
Animals
Humans
Integrins - agonists
Integrins - antagonists & inhibitors
Integrins - drug effects
Integrins - metabolism
Neovascularization, Pathologic
Patents as Topic
Protein Binding
Structure-Activity Relationship
Online AccessGet more information

Cover

More Information
Summary:Integrins are heterodimeric cell surface receptors, which enable adhesion, proliferation, and migration of cells by recognizing binding motifs in extracellular matrix (ECM) proteins. As transmembrane linkers between the cytoskeleton and the ECM, they are able to recruit a huge variety of proteins and to influence signaling pathways bidirectionally, thereby regulating gene expression and cell survival. Hence, integrins play a key role in various physiological as well as pathological processes, which has turned them into an attractive target for pharmaceutical research. In this review, the latest therapeutic developments of drug candidates and recently patented integrin ligands are summarized. Integrins have been proven to be valuable therapeutic targets in the treatment of several inflammatory and autoimmune diseases, where leukocyte adhesion processes are regulated by them. Furthermore, they play an important role in pathological angiogenesis and tumor metastasis, being a promising target for cancer therapy.
ISSN:1744-7674
DOI:10.1517/13543776.2013.818133